Navigation Links
New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Date:11/13/2007

business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended July 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
2. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
3. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Video: New Research Discovers Independent Brain Networks Control Human Walking
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. Enrollment Begins on Human PK Study for Medidur(TM) FA
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/3/2009)NEW YORK, Dec. 3 Guidepoint Global, LLC , a leading primary research firm, today announced the launch of their Sleep Apnea Tracker, a monthly longitudinal data release that monitors and projects tre
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Childbirth May Slow Progression of Multiple Sclerosis 62015 1Childbirth May Slow Progression of Multiple Sclerosis 62015 2Childbirth May Slow Progression of Multiple Sclerosis 62015 3DNA Genotek Launches Global Partner Program 14953 1DNA Genotek Launches Global Partner Program 14953 2DNA Genotek Launches Global Partner Program 14953 3Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 1Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 2Jackson 26amp 3B Coker Industry Report Addresses Health Care Reform 62010 3
... Company to Submit a Supplemental New Drug Applica..., Pa., April 6 Cephalon, Inc . (Nasdaq: CEPH )...ee clinical trial of NUVIGIL(R) (armodafinil) Tabl... associated with jet lag disorder. Based on these...w Drug Application with the U.S. Food and Drug Adm...
...pril 3 Torax Medical Inc., a medical device compa...gastroesophageal reflux disease (GERD) has commenc... Management System. The trial, which is being con...centers in the U.S. and Europe, will evaluate the ...ients suffering from GERD despite medical therapy....
Other Medicine Technology:Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 2Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 3Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder 4Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment 2
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
...dical, Inc.(TM), a leading medical technology comp...heral vascular disease, has completed the first hu...rossBoss(TM) CTO Catheter and Stingray(TM) CTO Re-... the treatment of completely blocked arteries know...
...rency firm change:healthcare has a prescription th...healthcare and financial distress. , ...9 -- The disappearance of 3.6 million jobs since D...the unpredictable cost of medical care can not onl...
...ties more supportive of stem cell research funding... A new national study conducted among 962 physicia... supportive of stem cell research than consumers a...e than half (55%) reported that they agree with fe...
...revention has improved, mortality rates are down, ...irculation from the Framingham Heart Study, which...nce in 9824 men and women over four decades, has p...d that over the past 40 years rates of AMI diagnos...
..., Inc. (OTC Bulletin Board: EMED), a leading provi...he Medical and Dental industries, has signed a con...l solutions to AmeriPlan(R) Corporation,s national... drugs, chiropractic, podiatry, medical, hospital ...
...l Alliance on Mental Illness (NAMI) Michigan relea...e state of mental health care in our state. The S...e in its rating . Fourteen states improved their g... further this year," said Sherri Solomon, Executiv...
Other Medicine News:Health News:BridgePoint Medical Completes First U.S. Clinical Case Using CrossBoss and Stingray Devices in CTO Angioplasty Procedure 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 2Health News:change:healthcare Helps Displaced Employees Immobilized by High Cost of Healthcare 3Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 2Health News:Docs More Supportive of Stem Cell Research Funding Than Consumers After Viewing President's Speech 3Health News:Explaining trends in heart attack 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 2Health News:MedCom Signs National Provider Contract With AmeriPlan Corporation 3Health News:Michigan's Mental Health Care System Gets a D Grade in Latest Study 2
New Image Cut-to-Fit Convex FlexWear Skin Barrier
New Image Closed Mini Pouch
CenterPointLock Stoma Irrigator Drain
CenterPointLock Sterile Drainable Kits
Medicine Products: